| DRUG WATCH |
|
| Year : 2012 | Volume
: 44
| Issue : 4 | Page : 533-535 |
Trimethoprim-sulfamethoxazole-induced Steven Johnson syndrome in an HIV-infected patient
Syed Ahmed Taqi1, Syed Ahmed Zaki2, Angadi Rajasab Nilofer2, Lateef Begum Sami3
1 Department of Oral Pathology and Microbiology, Bharthi Vidyapeeth University Dental College and Hospital, Navi Mumbai, India
2 Department of Pediatrics and Obstetrics and Gynecology, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, India
3 Department of Physiology, Mahatma Gandhi Mission Medical College and Hospital, Aurangabad, Maharashtra, India
Correspondence Address:
Syed Ahmed Zaki
Department of Pediatrics and Obstetrics and Gynecology, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.99346
Trimethoprim-sulfamethoxazole (TMP/SMX) is a widely prescribed antimicrobial for the management of several uncomplicated infections. It is commonly used for the treatment and prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in the HIV-infected population. The adverse reaction to TMP/SMX is more frequent and severe in HIV-infected patients as compared to the general population. Here, we report a case of Stevens-Johnson syndrome (SJS) secondary to TMP/SMX. The patient had a generalized cutaneous reaction with involvement of the eyes, oral cavity, and genitals. He had elevated hepatic alanine aminotransferase and aspartate aminotransferase enzyme. TMP/SMX therapy was stopped and supportive treatment was started. His condition improved after eight days of stopping TMP/SMX therapy.
[FULL TEXT] [PDF]*
|
